An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition)

Sarno G., 2012, Lower risk of stent thrombosis and restenosis with unrestricted access of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)., Eur Heart J., 33, 606, 10.1093/eurheartj/ehr479

Brugaletta S., 2012, Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?, Atherosclerosis., 221, 106, 10.1016/j.atherosclerosis.2011.12.008

Serruys PW., 2015, A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes of a randomised controlled trial., Lancet., 385, 43, 10.1016/S0140-6736(14)61455-0

Ormiston JA., 2009, Bioresorbable coronary stents., Circ Cardiovasc Interv., 2, 255, 10.1161/CIRCINTERVENTIONS.109.859173

Ormiston JA., 2014, Bioresorbable coronary scaffolds, Price MJ. Coronary Stenting: A Companion to Topol’s Textbook of Interventional Cardiology. Philadelphia, PA, USA: Elsevier

Ormiston JA., 2011, Bioresorbable polymeric vascular scaffolds: a cautionary tale., Circ Cardiovasc Interv., 4, 535, 10.1161/CIRCINTERVENTIONS.111.963710

Louvard Y., 2008, Classification of coronary artery bifurcation lesions and treatments: time for a consensus!, Catheter Cardiovasc Interv., 71, 175, 10.1002/ccd.21314

Ormiston JA., 2015, Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-dilatation strategies., EuroIntervention., 10, 1169, 10.4244/EIJY14M05_08

Kuntz RE., 1992, The importance of acute lumen diameter in determining restenosis after coronary atherectomy or stenting., Circulation., 86, 1827, 10.1161/01.CIR.86.6.1827

Ormiston JA., 2012, First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study., Circ Cardiovasc Interv., 5, 620, 10.1161/CIRCINTERVENTIONS.112.971549

Capodanno D., 2015, Percutaneous coronary ntervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry., EuroIntervention., 10, 1144, 10.4244/EIJY14M07_11

Hildick-Smith D., 2010, Consensus from the 5th European Bifurcation Club meeting., EuroIntervention., 6, 34, 10.4244/EIJV6I1A6

Lassen JF., 2014, Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings., EuroIntervention., 10, 545, 10.4244/EIJV10I5A97

Verheye S., 2014, The next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results., JACC Cardiovasc Interv., 7, 89, 10.1016/j.jcin.2013.07.007

Turco MA., 2008, Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program., JACC Cardiovasc Interv., 1, 699, 10.1016/j.jcin.2008.09.007

Ormiston JA., 2000, Stent longitudinal flexibility: a comparison of 13 stent designs before and after expansion., Catheter Cardiovasc Interv., 50, 120, 10.1002/(SICI)1522-726X(200005)50:1<120::AID-CCD26>3.0.CO;2-T

Serruys PW., 2009, A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods., Lancet., 373, 897, 10.1016/S0140-6736(09)60325-1

Okamura T., 2010, 3-Dimensional optical coherence tomographic assessment of jailed side branches by bioresorbable scaffolds: a proposal for classification., JACC Cardiovasc Interv., 3, 836, 10.1016/j.jcin.2010.05.011